GANX — Gain Therapeutics, Inc.
$1.26-2.33%
Last close: · regular session
After-hours $1.32 +4.76% ·
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for GANX in the TickerWise workspace.
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 23
- Website: https://www.gaintherapeutics.com
Latest SEC filings for GANX
Latest GANX news
- Gain Therapeutics to Attend the 2026 Maxim Growth Summit Read article
- Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration Read article
- Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson's Disease and Movement Disorders Read article
- Gain Therapeutics (NASDAQ:GANX) versus Spyre Therapeutics (NASDAQ:SYRE) Head to Head Comparison Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.